Pfizer Inc.  

(Public, NYSE:PFE)   Watch this stock  
Find more results for PFE
+0.40 (1.37%)
Feb 10 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 29.31 - 29.90
52 week 28.25 - 36.46
Open 29.33
Vol / Avg. 44.71M/37.50M
Mkt cap 185.55B
P/E 23.84
Div/yield 0.30/4.07
EPS 1.24
Shares 6.17B
Beta 0.90
Inst. own 74%
Apr 26, 2016
Q1 2016 Pfizer Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Apr 22, 2016
Pfizer Inc Annual Shareholders Meeting (Estimated) - 8:30AM EDT - Add to calendar
Feb 2, 2016
Q4 2015 Pfizer Inc Earnings Call
Feb 2, 2016
Q4 2015 Pfizer Inc Earnings Release
Jan 12, 2016
Allergan plc and Pfizer Inc at JPMorgan Healthcare Conference
Dec 15, 2015
Pfizer Inc at Guggenheim Boston Healthcare Conference
Dec 2, 2015
Pfizer Inc at Piper Jaffray Healthcare Conference
Nov 23, 2015
Pfizer Inc to Discuss Proposed Combination with Allergan Plc
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin 4.41% 15.88%
Operating margin 10.19% 22.62%
EBITD margin - 35.41%
Return on average assets - -
Return on average equity - -
Employees 78,300 -
CDP Score - 92 B


235 E 42ND ST
NEW YORK, NY 10017-5703
United States - Map
+1-212-5732323 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia


Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and women's/men's health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.

Officers and directors

Ian C. Read Chairman of the Board, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Frank A. D'Amelio Chief Financial Officer, Executive Vice President - Business Operations
Age: 57
Bio & Compensation  - Reuters
Albert Bourla Group President - Vaccines, Oncology and Consumer Healthcare Business
Age: 53
Bio & Compensation  - Reuters
Mikael Dolsten M.D., Ph.D. President - Worldwide Research and Development
Age: 56
Bio & Compensation  - Reuters
John D Young Group President - Global Established Pharma Business
Age: 50
Bio & Compensation  - Reuters
Rady A. Johnson II Executive Vice President, Chief Compliance and Risk Officer
Age: 53
Bio & Compensation  - Reuters
Douglas M. Lankler Executive Vice President, General Counsel
Age: 49
Bio & Compensation  - Reuters
Charles H. Hill III Executive Vice President - Worldwide Human Resources
Age: 59
Bio & Compensation  - Reuters
Freda C. Lewis-Hall M.D. Executive Vice President, Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Anthony J. Maddaluna Executive Vice President, President - Pfizer Global Supply
Age: 62
Bio & Compensation  - Reuters